Anavex Life Sciences (NASDAQ: AVXL)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.140 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Anavex Life Sciences (NASDAQ: AVXL) through any online brokerage.
Other companies in Anavex Life Sciences’s space includes: Avidity Biosciences (NASDAQ:RNA), Replimune Group (NASDAQ:REPL), Kiniksa Pharmaceuticals (NASDAQ:KNSA), PMV Pharma (NASDAQ:PMVP) and Alector (NASDAQ:ALEC).
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by Berenberg on Thursday, June 23, 2022. The analyst firm set a price target for 40.00 expecting AVXL to rise to within 12 months (a possible 304.45% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Anavex Life Sciences (NASDAQ: AVXL) is $9.89 last updated Today at June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Anavex Life Sciences.
Anavex Life Sciences’s Q3 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Anavex Life Sciences.
Anavex Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.